471 related articles for article (PubMed ID: 16107946)
1. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
3. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
Sterling TR; Chaisson RE; Keruly J; Moore RD
J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
[TBL] [Abstract][Full Text] [Related]
4. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
5. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
7. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
Moore DM; Hogg RS; Yip B; Craib K; Wood E; Montaner JS
HIV Med; 2006 Sep; 7(6):383-8. PubMed ID: 16903983
[TBL] [Abstract][Full Text] [Related]
8. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
9. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
10. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
11. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
14. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.
Sterling TR; Chaisson RE; Moore RD
Clin Infect Dis; 2003 Mar; 36(6):812-5. PubMed ID: 12627368
[TBL] [Abstract][Full Text] [Related]
15. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
17. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
19. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]